Data Insights

Odronextamab by Regeneron Pharmaceuticals for Follicular Lymphoma: Likelihood of Approval

Odronextamab is under clinical development by Regeneron Pharmaceuticals and currently in Phase II for Follicular Lymphoma. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Odronextamab in Follicular Lymphoma

Data Insights

Odronextamab by Regeneron Pharmaceuticals for Primary Mediastinal B-Cell Lymphoma: Likelihood of Approval

Odronextamab is under clinical development by Regeneron Pharmaceuticals and currently in Phase III for Primary Mediastinal B-Cell Lymphoma. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Odronextamab in Primary Mediastinal B-Cell Lymphoma

Data Insights

Odronextamab by Regeneron Pharmaceuticals for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia): Likelihood of Approval

Odronextamab is under clinical development by Regeneron Pharmaceuticals and currently in Phase II for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic...

Likelihood of Approval and Phase Transition Success Rate Model - Odronextamab in Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)

Data Insights

Odronextamab by Regeneron Pharmaceuticals for Marginal Zone B-cell Lymphoma: Likelihood of Approval

Odronextamab is under clinical development by Regeneron Pharmaceuticals and currently in Phase III for Marginal Zone B-cell Lymphoma. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Odronextamab in Marginal Zone B-cell Lymphoma

Data Insights

Odronextamab by Regeneron Pharmaceuticals for B-Cell Non-Hodgkin Lymphoma: Likelihood of Approval

Odronextamab is under clinical development by Regeneron Pharmaceuticals and currently in Phase III for B-Cell Non-Hodgkin Lymphoma. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Odronextamab in B-Cell Non-Hodgkin Lymphoma

Data Insights

Odronextamab by Regeneron Pharmaceuticals for Diffuse Large B-Cell Lymphoma: Likelihood of Approval

Odronextamab is under clinical development by Regeneron Pharmaceuticals and currently in Phase II for Diffuse Large B-Cell Lymphoma. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Odronextamab in Diffuse Large B-Cell Lymphoma

Data Insights

Risk adjusted net present value: What is the current valuation of Zai Lab's Odronextamab?

Odronextamab is a monoclonal antibody commercialized by Zai Lab, with a leading Phase III program in Marginal Zone B-cell Lymphoma....

Net Present Value Model: Zai Lab Ltd's Odronextamab

Data Insights

Risk adjusted net present value: What is the current valuation of Regeneron Pharmaceuticals's Odronextamab?

Odronextamab is a monoclonal antibody commercialized by Regeneron Pharmaceuticals, with a leading Phase III program in Marginal Zone B-cell Lymphoma....

Net Present Value Model: Regeneron Pharmaceuticals Inc's Odronextamab

Data Insights

Risk adjusted net present value: What is the current valuation of Zai Lab's Odronextamab?

Odronextamab is a monoclonal antibody commercialized by Zai Lab, with a leading Phase III program in Primary Mediastinal B-Cell Lymphoma....

Net Present Value Model: Zai Lab Ltd's Odronextamab